Immunovant reports Q1 fiscal 2026 results, says IMVT-1402 timelines on track
The company reported cash of $797.8 million as of June 30, 2026, and said all six IMVT-1402 disease programs remain on schedule.
Immunovant, Inc. (Nasdaq: IMVT) reported financial results for its fiscal first quarter ended June 30, 2026 on August 6, 2026. The company said its development plans for IMVT-1402 remain on track across all six announced indications.1
Those programs cover Graves' disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, difficult-to-treat rheumatoid arthritis, Sjögren's disease, and cutaneous lupus erythematosus. Immunovant said it expects to give further updates on its potentially registrational D2T RA program for IMVT-1402 and to report topline results from the proof-of-concept trial in cutaneous lupus erythematosus in the second half of calendar year 2026.1 The company anticipates topline data in calendar year 2027 from potentially registrational trials of IMVT-1402 in Graves' disease and myasthenia gravis, and topline data in calendar year 2028 from potentially registrational trials in CIDP and Sjögren's disease.1
On finances, Immunovant reported cash and cash equivalents of $797.8 million as of June 30, 2026, which it said provides runway to a potential commercial launch of IMVT-1402 in Graves' disease under its current operating plan.1
Research and development costs rose year over year. R&D expenses were $142.6 million for the quarter, up from $101.2 million a year earlier, which the company attributed mainly to IMVT-1402 clinical trial activity, including contract manufacturing costs, partly offset by lower spending as it winds down its batoclimab trials.1
General and administrative costs fell. G&A expenses were $17.7 million versus $26.0 million a year earlier, which the company said reflected lower personnel-related expenses, professional fees, market research costs, and information technology costs.1
Net loss widened for the period. Net loss was $153.2 million, or $0.75 per common share, compared with $120.6 million, or $0.71 per share, in the prior-year quarter.1
Immunovant describes itself as a clinical-stage immunology company focused on autoimmune diseases and states it is majority owned by Roivant (Nasdaq: ROIV).1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.